Thorofare, NJ – Healio has announced Joel M. Gelfand, MD, MSCE, as Chief Medical Editor of Healio Psoriatic Disease, the first publication focused on informing health care professionals about the burden of psoriatic disease and the emerging understanding of psoriasis as a systemic disease.
“We are thrilled to welcome Dr. Gelfand as Chief Medical Editor of Healio Psoriatic Disease,” Joan-Marie Stiglich, ELS, Chief Content Officer for Healio, said. “Along with being at the forefront of psoriasis research, education and patient treatment, he brings an abundance of energy and enthusiasm that will serve the publication and our readers well.”
Joel M. Gelfand, MD, MSCE, is Professor of Dermatology and Epidemiology (with tenure) in the Perelman School of Medicine at the University of Pennsylvania. He is also Vice Chair of Clinical Research, Medical Director of the Dermatology Clinical Studies Unit, and Director of the Psoriasis and Phototherapy Treatment Center at Penn Medicine. He is a nationally and internationally recognized expert in psoriasis, clinical epidemiology, drug safety, and clinical trials. Dr. Gelfand is the author of over 260 scientific publications, editorials, reviews, and text book chapters which appear in journals such as JAMA, BMJ, European Heart Journal, Annals of Rheumatic Disease, JAMA Dermatology, JAAD, and the JID. He is a past Associate Editor of Pharmacoepidemiology and Drug Safety, past Editorial Board Member of the Journal of the American Academy of Dermatology, and is currently Deputy Editor of the Journal Investigative Dermatology. He is the recipient of the American Skin Association’s Psoriasis Achievement Award, PENN’s New Investigator Marjorie Bowman Award and the Lady Barbara Colyton’s Award for Autoimmune research, Penn’s Department of Biostatistics and Epidemiology’s epidemiology teaching award, National Psoriasis Foundation’s (NPF) inaugural award for scientific achievement, and is an elected member of the American Society for Clinical Investigation. He Co-Chairs the NPF’s COVID-19 task force, and is a member of the Board of Directors for the International Psoriasis Council. He is a co-author of the AAD-NPF joint guidelines of care for psoriasis. He has given over 10 named lectureships and keynote addresses including the Society for Investigative Dermatology’s Eugene M. Farber lecture and the American Academy of Dermatology’s Marion B. Sulzberger lecture. He has received grant support from NIH, FDA, PCORI, the Dermatology Foundation, the American Skin Association, the NPF, and numerous pharmaceutical companies to support his independent research program. The overarching goal of his research and clinical practice is to improve psoriasis patient outcomes in the skin and joints, while lowering the risk of diabetes, CV disease and mortality.
“I am delighted to work with the outstanding editorial professionals at Healio to help communicate key advances in psoriasis to the thousands of dermatologists, rheumatologists, and other medical professionals worldwide who regularly read Healio Psoriatic Disease and are dedicated to improving patient outcomes,” said Dr. Gelfand.
Healio Psoriatic Disease features coverage of the latest peer-reviewed research, meeting news highlights and FDA approvals related to psoriatic disease and other dermatological conditions.
Healio is a multichannel information platform, providing health care specialists with tailored news, information and education in support of their daily practice of medicine. An in-depth, clinical information resource, Healio brings together award-winning news reporting with expert perspectives, dynamic video and multimedia, question-and-answer columns, CME and other custom educational activities, blogs, peer-reviewed journals and a wide range of popular medical book titles all in one place. For more information, visit Healio.com.